Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer
Open Access
- 1 June 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (6), 1137-1141
- https://doi.org/10.1158/1055-9965.epi-05-0823
Abstract
Some recent epidemiologic studies have failed to confirm positive associations between insulin-like growth factor-I (IGF-I) and the risk of prostate cancer observed in earlier studies but have reported suggestive evidence for a positive association between IGF-binding protein-3 (IGFBP-3) and prostate cancer risk, a result contradicting the earlier assumption that high levels of IGFBP-3 would be protective against prostate cancer. We tested the association between IGF-I and IGFBP-3 and prostate cancer risk by measuring the two peptides in plasma samples collected at baseline in a prospective cohort study of 17,049 men. We used a case-cohort design, including 524 cases diagnosed during a mean of 8.7 years follow-up and a randomly sampled subcohort of 1,826 men. The association between each peptide level and prostate cancer risk was tested using Cox models adjusted for country of birth and alcohol consumption. The risk of prostate cancer was not associated with baseline levels of IGF-I or the molar ratio IGF-I/IGFBP-3 (all odds ratios are between 0.82 and 1.08; Ptrend ≥ 0.2), whereas the risk increased with baseline levels of IGFBP-3 (Ptrend = 0.008), the hazard ratio (HR) associated with a doubling of the concentration of IGFBP-3 being 1.70 (95% confidence interval, 1.15-2.52). The HR for quartile 4 relative to quartile 1 of IGFBP-3 was 1.49 (95% confidence interval, 1.11-2.00). The HRs did not differ by tumor aggressiveness or age at onset (all Ps ≥ 0.4). In our study, high levels of IGFBP-3 but not IGF-I were associated with an increased risk of prostate cancer. (Cancer Epidemiol Biomarkers Prev 2006;15(6):1137–41)Keywords
This publication has 26 references indexed in Scilit:
- Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA eraCancer Causes & Control, 2005
- Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin‐like growth factor I, insulin‐like growth factor binding protein 3, and insulinCancer, 2004
- High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened CohortJournal of Clinical Oncology, 2004
- Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysisThe Lancet, 2004
- Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer CellsPublished by Elsevier BV ,2002
- Serum Levels of Insulin-Like Growth Factor I (IGF-I), IGF-II, IGF-Binding Protein-3, and Prostate-Specific Antigen as Predictors of Clinical Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2000
- The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic GrowthEndocrine Reviews, 2000
- Systemic Administration of Insulin-Like Growth Factor I (IGF-I) Causes Growth of the Rat ProstateJournal of Urology, 1997
- The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor geneMolecular Endocrinology, 1995
- A case-cohort design for epidemiologic cohort studies and disease prevention trialsBiometrika, 1986